Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A sensitive spectrophotometric method for the determination of sulfonamides in pharmaceutical preparations

A sensitive spectrophotometric method for the determination of sulfonamides in pharmaceutical... Acta Pharm. 57 (2007) 333­342 10.2478/v10007-007-0026-4 Original research paper PADMARAJAIAH NAGARAJA1* SHAILENDRA D. NAIK2 ASHWINEE KUMAR SHRESTHA1 ANANTHARAMAN SHIVAKUMAR1 1 Department of Studies in Chemistry University of Mysore, Manasagangothri Mysore-570006, India Charak Pharma Pvt. Ltd., Silvassa U. T. of Dadra Nagar Haveli Silvassa-396230, India A new, simple and sensitive spectrophotometric method for the determination of some sulfonamide drugs has been developed. The method is based on the diazotization of sulfacetamide, sulfadiazine, sulfaguanidine, sulfamerazine, sulfamethazine, sulfamethoxazole, and their coupling with 8-hydroxyquinoline in alkaline media to yield red coloured products with absorption maxima at 500 nm. Beer's law is obeyed from 0.1­7.0 mg mL­1. The limits of quantification and limits of detection were 0.11­0.18 and 0.03­0.05 mg mL­1, respectively. Intraday precision (RSD 0.1­ 0.5%) and accuracy (recovery 97.3­100.8%) of the developed method were evaluated. No interference was observed from common adjuvants. The method has been successfully applied to the assay of sulpha drug in pharmaceutical formulations. Keywords: sulfonamide drugs, diazotization, 8-hydroxyquinoline, spectrophotometry, pharmaceutical formulation Accepted June 26, 2007 Sulfonamides, important analogues of p-amino benzoic acid (1), are used in the treatment of urinary track infections, eye infections and as a prophylaxis of rheumatic fever (2). Antibacterial sulfonamides act as competitive inhibitors of the enzyme dihydropteroate synthetase, DHPS, in bacteria. DHPS catalyses the conversion of PABA (p-aminobenzoate) to dihydropteroate, a key step in folate synthesis, which is necessary for the cell to synthesize nucleic acids and thus exhibit a bacteriostatic effect (3). Survey of the literature reveals various methods available for the determination of sulfonamide derivatives. The methods include the nitrite method (4), GC (5), HPLC (6, 7), HPTLC (8), electroanalytical methods (9­12), immune chemical assay (13, 14), spectrofluorimetry (15), differential scanning calorimetry (16), surface enhanced Raman spectrometry (17), spectrophotometry (18­22). Most spectrophotometric methods suffer from low sensitivity, high detection limits, tedious experimental conditions and complex procedures for the preparation of samples or standard solutions. In the present study, we succeeded in developing a novel coupling agent for sensitive and selective spectrophotometric determination of the sulfonamide class of drugs * Correspondence, e-mail: nagarajap58@yahoo.co.in based on the coupling of their diazotized form with 8-hydroxyquinoline (8-HQ), which results in the formation of red coloured products in alkaline medium. EXPERIMENTAL Apparatus A CHEMITO Model 2100 UV-VIS Spectrophotometer (Chemito Technologies Pvt Ltd., India) with 1-cm matched cells was used for all spectral and absorbance measurements. Reagents All the reagents and solvents were of analytical grade. The drugs selected for study were procured from Charak Pharma Pvt. Ltd. (India), and their structures are given in Table I: sulfacetamide (SFA, 99.0%, Sigma Spain), sulfamethazine (SFMt, 99.0%, Sigma China), sulfadiazine (SFD, 99.0%, Sigma China) sulfaguanidine (SFG, 99.0%, Sigma Switzerland), sulfamerazine (SFMr, 99.0%, Sigma Belgium), sulfamethoxazole (SFMx, 99.0%, Sigma Belgium). Table I. Sulfonamide drugs studied Drug (code) Sulfacetamide (SFA) Structure Sulfadiazine (SFD) SO2NH N Sulfaguanidine (SFG) SO2NC(NH2)2 CH3 N Sulfamerazine (SFMr) SO2NH N CH3 N Sulfamethazine (SFMt) SO2NH N CH3 Sulfamethoxazole (SFMx) SO2NH N O CH3 Standard solution of sulfonamide (1000 mg mL­1) was prepared by dissolving 100 mg each sulfonamide in 2.0 mL of sulfuric acid (10 mol L­1), then diluting with water to mark in a 100-mL volumetric flask. A working standard solution of each sulfonamide containing 25 mg mL­1 was prepared by further dilution and was standardized by the British Pharmacopoeia method (4) and the reported method (21). An 8-HQ solution (0.5%, m/V), sodium nitrite (1.0%, m/V) sulphamic acid (2%, m/V), sodium hydroxide (5 mol L­1) and sulphuric acid (10 mol L­1) were prepared in water. General procedure Aliquots of standard sulfonamide solutions (SFMx, SFD, SFA, SFMt, SFMr and SFG) were transferred into 25-mL calibrated flasks followed by 1.0 mL sulphuric acid to each. After cooling in an ice bath, 1.5 mL of sodium nitrite (1.0% m/V) was added under swirling. The solutions were allowed to stand for 5 min and then 2.5 mL of sulphamic acid (2.0%, m/V) was added, swirled and allowed to stand for 5 min. Then 2.0 mL of 8-HQ (0.5%, m/V) was added, along with 2.0 mL of sodium hydroxide (5 mol L­1). The solution was made up to the mark with ethanol (95%), mixed thoroughly and after 5 min the absorbance was measured at 500 nm against a reagent blank, and the calibration graph was constructed. The limit of detection (LOD) and quantification (LOQ) were calculated according to the current ICH guidelines (23) as 3.3 and 10 standard deviation of the blank (n = 6) respectively, divided by the slope of the calculation curve. The range of the error was calculated using the following mathematical relation (24): ± t SD n where t = 2.571 (95% confidence limit), n = number of replicate determinations. Assay of commercial samples Tablets. ­ The following tablet formulations were purchased from local commercial sources and used for the analysis: Septran tablet (Burroughs Wellcome, India) each containing 400 mg of SFMx, Sulphadiazine tablet (Rhone Poulenc, India) each containing 500 mg of SFD. Twenty tablets were powdered and mixed thoroughly. An amount equivalent to 50 mg sulfonamide was then dissolved in 20 mL of sulphuric acid (1 mol L­1) and filtered. The filtrate was made up to 100 mL and appropriate aliquots of the solution were treated as mentioned above in the general procedure. Eye drops. ­ The following eye drop formulations were purchased from local sources and used for the analysis: Albucid (Nicholos-Pharmal India Ltd., India) containing 10 mg SFA mL­1, Locula (East India Ltd., India) containing 10 mg SFA mL­1. A volume of 5 mL of eye drops (equivalent to 50 mg of SFA) was diluted with 2 mL of sulphuric acid (10 mol L­1) and made up to 100 mL with water. The general procedure was then followed. RESULTS AND DISCUSSION Chemistry Sulfa drugs could be readily diazotized in acidic medium and the diazonium cation would then react with a molecule of 8-HQ by electrophilic substitution at position-4 of the coupling agent. The proposed method involves diazotization of sulfonamide derivatives followed by their coupling with 8-HQ to produce a red coloured azo product. Job's method of continuous variation for determining the composition of the product indicated that the reactants and reagents reacted in the 1:1 ratio. The proposed mechanism of reaction between 8-HQ and the sulfonamide drug is illustrated in Fig. 1. To ascertain the absorption maxima for sulfonamide derivatives, specified amounts of sulfonamide derivatives were taken and the coloured reaction products were developed as mentioned in the general procedure, and the absorption maxima were found to be 500 nm. Fig. 2 shows the absorption spectrum of SFMx as the model compound. The resultant coloured product was found to be stable for about two days. The value of absorbance decreased above 30 °C. Hence, room temperature was preferred for the experiments. An attempt to increase the stability of the product beyond 48 hours failed. NO2­ SFA OH N N2+ diazotized SFA coupled product Fig 1. Scheme of the proposed reaction mechanism. Diazotised SFMx + 8-HQ Blank Absorbance Wavelength (nm) Fig. 2. Absorption spectrum of the reaction product of sulfamethoxazole (SFMx) with 8-HQ (lmax= 500 nm). Validation The intraday precision of the proposed method was examined by carrying out six replicate determinations of sulfonamides (within Beer's law range) by the proposed method. Table II summarizes the RSD values (0.1­0.5%) and the range of error (0.20­0.35 at 95% confidence limit). The LOD was found to be in the range of 0.03 to 0.05 mg mL­1 and LOQ was in the range of 0.11 to 0.18 mg mL­1. The recovery ranged from 97.3 ± 2.5% to 100.8 ± 1.2% (n = 6) (Table III). The most promising feature of the proposed method is the freedom from interferences with the excipients commonly used in the pharmaceutical preparation of sulfonamide derivatives. Under optimum conditions, the effects of excipients and diluents such as talc, glucose, dextrose, lactose, etc., were investigated. An amount far in excess of that used in the pharmaceutical preparation was added in half the limit of Beer's law and no effect due to these excipients was found under the proposed experimental conditions. The recovery range was from 99.2 ± 0.2% to 100.8 ± 0.4% (n = 6). The results are presented in Table IV. Application of the proposed method The applicability of the proposed method for the assay of different pharmaceutical formulations containing SFMx, SFD and SFA was examined for tablet and eye drops and the results were statistically compared with those obtained by the official method based on electrochemical titration (4) with NaNO2 and the reported spectrophotometric method (21) based on the reaction of drug with acetylacetone-formaldehyde reagent. The t-test and F-test were carried out, which showed that the proposed method and other established methods are of comparable accuracy and precision. The results are summarized in Table V. Table II. Some analytical parametres for the spectrophotometric determination of sulfonamide derivatives Parameter Colour ëmax (nm) Stability (h) Beer's law range (mg mL­1) Limit of detection (mg mL­1) Limit of quantitation (mg mL­1) Molar absorptivity (L mol­1 cm­1) SFMx Red 500 48 0.2­6.0 0.04 0.15 SFD Red 500 48 0.1­5.0 0.05 0.16 SFA Red 500 42 0.2­6.0 0.04 0.15 SFMt Red 500 48 0.3­7.0 0.04 0.18 SFMr Red 500 46 0.03 0.12 SFG Red 500 48 0.03 0.11 0.1­4.0 0.19­6.0 3.38 x 104 3.7 x 104 2.81 x 104 3.48 x 104 3.8 x 104 3.7 x 104 Regression equation (y)a Slope (a) Intercept (b) Correlation coefficient (R) RSD (%) Range of error (95% confidencee level) (%) y = a ã + b where ã is the concentration in mg mL­1. Table III. Intraday accuracy and precision of the proposed method for SFMx SFMx found (%)a Reported method (21) 99.7 ± 1.8 Proposed methodb 97.3 ± 2.5 t = 2.41 F = 1.93 99.6 ± 1.3 t = 0.75 F = 2.10 99.7 ± 1.4 t = 0.35 F = 1.36 97.9 ± 1.0 t = 1.70 F = 1.44 100.8 ± 1.2 t = 2.12 F = 1.44 Nominal concentration SFMx (mg mL­1) 1.0 (er) (%) 2.4 Paired t-test 2.005 99.2 ± 0.9 99.5 ± 1.2 97.3 ± 1.2 99.7 ± 1.0 a b Mean ± SD, n = 6. Tabular t-value for d.f. 5 is 2.571; Tabular F-value for d.f. 5 is 5.05. Table IV. Interference studies of commonly used excipients Recovery (%)a,b SFMx SFD SFA SFMt SFMr SFG Exicipient Gum acacia Talc Starch Dextrose Glucose Lactose Carboxymethylcellulose Magnesium stearate Sodium alginate Vitamin B6 a b Conc. (mg mL­1) 5.0 5.0 5.0 3.5 3.0 4.0 4.0 3.0 4.0 3.8 99.5 ± 0.3 99.2 ± 0.3 100.5 ± 0.2 99.2 ± 0.3 100.1 ± 0.3 99.2 ± 0.3 100.1 ± 0.3 99.5 ± 0.3 99.2 ± 0.4 100.4 ± 0.3 100.1 ± 0.3 99.5 ± 0.3 99.2 ± 0.3 99.2 ± 0.3 99.2 ± 0.3 99.4 ± 0.2 100.2 ± 0.2 99.6 ± 0.3 99.2 ± 0.3 99.5 ± 0.3 99.6 ± 0.3 99.5 ± 0.3 99.6 ± 0.3 99.2 ± 0.3 99.6 ± 0.3 99.5 ± 0.3 99.7 ± 0.2 99.2 ± 0.3 99.6 ± 0.3 95.5 ± 0.3 100.2 ± 0.3 100.1 ± 0.3 100.2 ± 0.2 99.2 ± 0.5 100.7 ± 0.3 99.9 ± 0.2 100.5 ± 0.3 99.2 ± 0.2 100.2 ± 0.2 100.8 ± 0.4 100.6 ± 0.3 99.8 ± 0.4 99.2 ± 0.3 99.2 ± 0.3 99.8 ± 0.2 99.7 ± 0.3 100.2 ± 0.2 99.9 ± 0.2 99.3 ± 0.6 99.6 ± 0.3 99.8 ± 0.3 99.2 ± 0.5 99.9 ± 0.2 99.1 ± 0.3 100.3 ± 0.3 100.2 ± 0.3 100.6 ± 0.3 100.7 ± 0.4 100.3 ± 0.3 100.2 ± 0.3 Concentration of sulfonamide drug: 4 ìg mL­1. Mean ± SD, n = 6. The reported methods and the proposed method are compared in Table VI. For example, the proposed method is more simple and sensitive than the method including drug diazotization coupling with dopamine followed by complexation with molybdate ion reported earlier (28). Table V. Determination of sulfonamide derivatives in pharmaceutical preparations Amount of drug found (in mg)a Sample Septran (mg SFMx) Sulphadiazine (mg SFD) Albucid (mg mL­1 SFA) Locula (mg mL­1 SFA) Label claim 400 500 10 10 Proposed method 398.00 ± 0.70 497.00 ± 0.50 9.90 ± 0.30 9.85 ± 0.20 BP method (4) 397.00 ± 0.60 496.00 ± 0.60 9.90 ± 0.30 9.80 ± 0.30 Reported method (21) 397.00 ± 0.80 496.00 ± 0.80 9.75 ± 0.30 9.78 ± 0.30 t-value F-value 2.29 2.29 2.48 2.50 1.44 1.44 2.25 1.96 a Mean ± SD, n = 6. Theoretical t-value = 2.776; theoretical F-value = 6.39. Table VI. Comparison of reported spectrophotometric methods with the proposed method Sulfonamide ëmax (nm) analyzed SFMx and SFD SFA SFG 500 525 450 Beer's law limits (mg mL­1) 10­50 10­70 Not reported 0.1­7.0 1.65 ´ 104 Molar absorptivity Reference (L mol­1 cm­1) 25 26 27 Reagent(s) used p-Benzoquinone o-Chloranil Phenol and sodium hypochlorite Dopamine Remark heating is needed SFMx 2.67 ´ 104 diazotisation coupling, product is complexaton with molybdate diazotization of drug followed by coupling with 8-HQ 8-Hydroxyquinoline (8-HQ) SFMx 0.2­6.0 3.38 ´ 104 this paper The proposed method was found to be simple, rapid, selective and more sensitive than most of the spectrophotometric methods available in literature. It does not involve heating, extraction and consumes less time. The products are stable for a sufficient interval of time making the method useful in practice. CONCLUSIONS The proposed method is simple, sensitive and free from drastic experimental conditions such as heating. It is also accurate and precise enough to be successfully adopted as an alternative to the existing spectrophotometric method and evaluation of drugs in pharmaceutical preparations to assure a high standard of quality control. Acknowledgements. ­ One of the authors (Shailendra D. Naik) thanks the University of Mysore for the support to this research work. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Pharmaceutica de Gruyter

A sensitive spectrophotometric method for the determination of sulfonamides in pharmaceutical preparations

Download PDF
10 pages

Loading next page...
 
/lp/de-gruyter/a-sensitive-spectrophotometric-method-for-the-determination-of-KJ2DXw1Shb
Publisher
de Gruyter
Copyright
Copyright © 2007 by the
ISSN
1330-0075
eISSN
1846-9558
DOI
10.2478/v10007-007-0026-4
pmid
17878112
Publisher site
See Article on Publisher Site

Abstract

Acta Pharm. 57 (2007) 333­342 10.2478/v10007-007-0026-4 Original research paper PADMARAJAIAH NAGARAJA1* SHAILENDRA D. NAIK2 ASHWINEE KUMAR SHRESTHA1 ANANTHARAMAN SHIVAKUMAR1 1 Department of Studies in Chemistry University of Mysore, Manasagangothri Mysore-570006, India Charak Pharma Pvt. Ltd., Silvassa U. T. of Dadra Nagar Haveli Silvassa-396230, India A new, simple and sensitive spectrophotometric method for the determination of some sulfonamide drugs has been developed. The method is based on the diazotization of sulfacetamide, sulfadiazine, sulfaguanidine, sulfamerazine, sulfamethazine, sulfamethoxazole, and their coupling with 8-hydroxyquinoline in alkaline media to yield red coloured products with absorption maxima at 500 nm. Beer's law is obeyed from 0.1­7.0 mg mL­1. The limits of quantification and limits of detection were 0.11­0.18 and 0.03­0.05 mg mL­1, respectively. Intraday precision (RSD 0.1­ 0.5%) and accuracy (recovery 97.3­100.8%) of the developed method were evaluated. No interference was observed from common adjuvants. The method has been successfully applied to the assay of sulpha drug in pharmaceutical formulations. Keywords: sulfonamide drugs, diazotization, 8-hydroxyquinoline, spectrophotometry, pharmaceutical formulation Accepted June 26, 2007 Sulfonamides, important analogues of p-amino benzoic acid (1), are used in the treatment of urinary track infections, eye infections and as a prophylaxis of rheumatic fever (2). Antibacterial sulfonamides act as competitive inhibitors of the enzyme dihydropteroate synthetase, DHPS, in bacteria. DHPS catalyses the conversion of PABA (p-aminobenzoate) to dihydropteroate, a key step in folate synthesis, which is necessary for the cell to synthesize nucleic acids and thus exhibit a bacteriostatic effect (3). Survey of the literature reveals various methods available for the determination of sulfonamide derivatives. The methods include the nitrite method (4), GC (5), HPLC (6, 7), HPTLC (8), electroanalytical methods (9­12), immune chemical assay (13, 14), spectrofluorimetry (15), differential scanning calorimetry (16), surface enhanced Raman spectrometry (17), spectrophotometry (18­22). Most spectrophotometric methods suffer from low sensitivity, high detection limits, tedious experimental conditions and complex procedures for the preparation of samples or standard solutions. In the present study, we succeeded in developing a novel coupling agent for sensitive and selective spectrophotometric determination of the sulfonamide class of drugs * Correspondence, e-mail: nagarajap58@yahoo.co.in based on the coupling of their diazotized form with 8-hydroxyquinoline (8-HQ), which results in the formation of red coloured products in alkaline medium. EXPERIMENTAL Apparatus A CHEMITO Model 2100 UV-VIS Spectrophotometer (Chemito Technologies Pvt Ltd., India) with 1-cm matched cells was used for all spectral and absorbance measurements. Reagents All the reagents and solvents were of analytical grade. The drugs selected for study were procured from Charak Pharma Pvt. Ltd. (India), and their structures are given in Table I: sulfacetamide (SFA, 99.0%, Sigma Spain), sulfamethazine (SFMt, 99.0%, Sigma China), sulfadiazine (SFD, 99.0%, Sigma China) sulfaguanidine (SFG, 99.0%, Sigma Switzerland), sulfamerazine (SFMr, 99.0%, Sigma Belgium), sulfamethoxazole (SFMx, 99.0%, Sigma Belgium). Table I. Sulfonamide drugs studied Drug (code) Sulfacetamide (SFA) Structure Sulfadiazine (SFD) SO2NH N Sulfaguanidine (SFG) SO2NC(NH2)2 CH3 N Sulfamerazine (SFMr) SO2NH N CH3 N Sulfamethazine (SFMt) SO2NH N CH3 Sulfamethoxazole (SFMx) SO2NH N O CH3 Standard solution of sulfonamide (1000 mg mL­1) was prepared by dissolving 100 mg each sulfonamide in 2.0 mL of sulfuric acid (10 mol L­1), then diluting with water to mark in a 100-mL volumetric flask. A working standard solution of each sulfonamide containing 25 mg mL­1 was prepared by further dilution and was standardized by the British Pharmacopoeia method (4) and the reported method (21). An 8-HQ solution (0.5%, m/V), sodium nitrite (1.0%, m/V) sulphamic acid (2%, m/V), sodium hydroxide (5 mol L­1) and sulphuric acid (10 mol L­1) were prepared in water. General procedure Aliquots of standard sulfonamide solutions (SFMx, SFD, SFA, SFMt, SFMr and SFG) were transferred into 25-mL calibrated flasks followed by 1.0 mL sulphuric acid to each. After cooling in an ice bath, 1.5 mL of sodium nitrite (1.0% m/V) was added under swirling. The solutions were allowed to stand for 5 min and then 2.5 mL of sulphamic acid (2.0%, m/V) was added, swirled and allowed to stand for 5 min. Then 2.0 mL of 8-HQ (0.5%, m/V) was added, along with 2.0 mL of sodium hydroxide (5 mol L­1). The solution was made up to the mark with ethanol (95%), mixed thoroughly and after 5 min the absorbance was measured at 500 nm against a reagent blank, and the calibration graph was constructed. The limit of detection (LOD) and quantification (LOQ) were calculated according to the current ICH guidelines (23) as 3.3 and 10 standard deviation of the blank (n = 6) respectively, divided by the slope of the calculation curve. The range of the error was calculated using the following mathematical relation (24): ± t SD n where t = 2.571 (95% confidence limit), n = number of replicate determinations. Assay of commercial samples Tablets. ­ The following tablet formulations were purchased from local commercial sources and used for the analysis: Septran tablet (Burroughs Wellcome, India) each containing 400 mg of SFMx, Sulphadiazine tablet (Rhone Poulenc, India) each containing 500 mg of SFD. Twenty tablets were powdered and mixed thoroughly. An amount equivalent to 50 mg sulfonamide was then dissolved in 20 mL of sulphuric acid (1 mol L­1) and filtered. The filtrate was made up to 100 mL and appropriate aliquots of the solution were treated as mentioned above in the general procedure. Eye drops. ­ The following eye drop formulations were purchased from local sources and used for the analysis: Albucid (Nicholos-Pharmal India Ltd., India) containing 10 mg SFA mL­1, Locula (East India Ltd., India) containing 10 mg SFA mL­1. A volume of 5 mL of eye drops (equivalent to 50 mg of SFA) was diluted with 2 mL of sulphuric acid (10 mol L­1) and made up to 100 mL with water. The general procedure was then followed. RESULTS AND DISCUSSION Chemistry Sulfa drugs could be readily diazotized in acidic medium and the diazonium cation would then react with a molecule of 8-HQ by electrophilic substitution at position-4 of the coupling agent. The proposed method involves diazotization of sulfonamide derivatives followed by their coupling with 8-HQ to produce a red coloured azo product. Job's method of continuous variation for determining the composition of the product indicated that the reactants and reagents reacted in the 1:1 ratio. The proposed mechanism of reaction between 8-HQ and the sulfonamide drug is illustrated in Fig. 1. To ascertain the absorption maxima for sulfonamide derivatives, specified amounts of sulfonamide derivatives were taken and the coloured reaction products were developed as mentioned in the general procedure, and the absorption maxima were found to be 500 nm. Fig. 2 shows the absorption spectrum of SFMx as the model compound. The resultant coloured product was found to be stable for about two days. The value of absorbance decreased above 30 °C. Hence, room temperature was preferred for the experiments. An attempt to increase the stability of the product beyond 48 hours failed. NO2­ SFA OH N N2+ diazotized SFA coupled product Fig 1. Scheme of the proposed reaction mechanism. Diazotised SFMx + 8-HQ Blank Absorbance Wavelength (nm) Fig. 2. Absorption spectrum of the reaction product of sulfamethoxazole (SFMx) with 8-HQ (lmax= 500 nm). Validation The intraday precision of the proposed method was examined by carrying out six replicate determinations of sulfonamides (within Beer's law range) by the proposed method. Table II summarizes the RSD values (0.1­0.5%) and the range of error (0.20­0.35 at 95% confidence limit). The LOD was found to be in the range of 0.03 to 0.05 mg mL­1 and LOQ was in the range of 0.11 to 0.18 mg mL­1. The recovery ranged from 97.3 ± 2.5% to 100.8 ± 1.2% (n = 6) (Table III). The most promising feature of the proposed method is the freedom from interferences with the excipients commonly used in the pharmaceutical preparation of sulfonamide derivatives. Under optimum conditions, the effects of excipients and diluents such as talc, glucose, dextrose, lactose, etc., were investigated. An amount far in excess of that used in the pharmaceutical preparation was added in half the limit of Beer's law and no effect due to these excipients was found under the proposed experimental conditions. The recovery range was from 99.2 ± 0.2% to 100.8 ± 0.4% (n = 6). The results are presented in Table IV. Application of the proposed method The applicability of the proposed method for the assay of different pharmaceutical formulations containing SFMx, SFD and SFA was examined for tablet and eye drops and the results were statistically compared with those obtained by the official method based on electrochemical titration (4) with NaNO2 and the reported spectrophotometric method (21) based on the reaction of drug with acetylacetone-formaldehyde reagent. The t-test and F-test were carried out, which showed that the proposed method and other established methods are of comparable accuracy and precision. The results are summarized in Table V. Table II. Some analytical parametres for the spectrophotometric determination of sulfonamide derivatives Parameter Colour ëmax (nm) Stability (h) Beer's law range (mg mL­1) Limit of detection (mg mL­1) Limit of quantitation (mg mL­1) Molar absorptivity (L mol­1 cm­1) SFMx Red 500 48 0.2­6.0 0.04 0.15 SFD Red 500 48 0.1­5.0 0.05 0.16 SFA Red 500 42 0.2­6.0 0.04 0.15 SFMt Red 500 48 0.3­7.0 0.04 0.18 SFMr Red 500 46 0.03 0.12 SFG Red 500 48 0.03 0.11 0.1­4.0 0.19­6.0 3.38 x 104 3.7 x 104 2.81 x 104 3.48 x 104 3.8 x 104 3.7 x 104 Regression equation (y)a Slope (a) Intercept (b) Correlation coefficient (R) RSD (%) Range of error (95% confidencee level) (%) y = a ã + b where ã is the concentration in mg mL­1. Table III. Intraday accuracy and precision of the proposed method for SFMx SFMx found (%)a Reported method (21) 99.7 ± 1.8 Proposed methodb 97.3 ± 2.5 t = 2.41 F = 1.93 99.6 ± 1.3 t = 0.75 F = 2.10 99.7 ± 1.4 t = 0.35 F = 1.36 97.9 ± 1.0 t = 1.70 F = 1.44 100.8 ± 1.2 t = 2.12 F = 1.44 Nominal concentration SFMx (mg mL­1) 1.0 (er) (%) 2.4 Paired t-test 2.005 99.2 ± 0.9 99.5 ± 1.2 97.3 ± 1.2 99.7 ± 1.0 a b Mean ± SD, n = 6. Tabular t-value for d.f. 5 is 2.571; Tabular F-value for d.f. 5 is 5.05. Table IV. Interference studies of commonly used excipients Recovery (%)a,b SFMx SFD SFA SFMt SFMr SFG Exicipient Gum acacia Talc Starch Dextrose Glucose Lactose Carboxymethylcellulose Magnesium stearate Sodium alginate Vitamin B6 a b Conc. (mg mL­1) 5.0 5.0 5.0 3.5 3.0 4.0 4.0 3.0 4.0 3.8 99.5 ± 0.3 99.2 ± 0.3 100.5 ± 0.2 99.2 ± 0.3 100.1 ± 0.3 99.2 ± 0.3 100.1 ± 0.3 99.5 ± 0.3 99.2 ± 0.4 100.4 ± 0.3 100.1 ± 0.3 99.5 ± 0.3 99.2 ± 0.3 99.2 ± 0.3 99.2 ± 0.3 99.4 ± 0.2 100.2 ± 0.2 99.6 ± 0.3 99.2 ± 0.3 99.5 ± 0.3 99.6 ± 0.3 99.5 ± 0.3 99.6 ± 0.3 99.2 ± 0.3 99.6 ± 0.3 99.5 ± 0.3 99.7 ± 0.2 99.2 ± 0.3 99.6 ± 0.3 95.5 ± 0.3 100.2 ± 0.3 100.1 ± 0.3 100.2 ± 0.2 99.2 ± 0.5 100.7 ± 0.3 99.9 ± 0.2 100.5 ± 0.3 99.2 ± 0.2 100.2 ± 0.2 100.8 ± 0.4 100.6 ± 0.3 99.8 ± 0.4 99.2 ± 0.3 99.2 ± 0.3 99.8 ± 0.2 99.7 ± 0.3 100.2 ± 0.2 99.9 ± 0.2 99.3 ± 0.6 99.6 ± 0.3 99.8 ± 0.3 99.2 ± 0.5 99.9 ± 0.2 99.1 ± 0.3 100.3 ± 0.3 100.2 ± 0.3 100.6 ± 0.3 100.7 ± 0.4 100.3 ± 0.3 100.2 ± 0.3 Concentration of sulfonamide drug: 4 ìg mL­1. Mean ± SD, n = 6. The reported methods and the proposed method are compared in Table VI. For example, the proposed method is more simple and sensitive than the method including drug diazotization coupling with dopamine followed by complexation with molybdate ion reported earlier (28). Table V. Determination of sulfonamide derivatives in pharmaceutical preparations Amount of drug found (in mg)a Sample Septran (mg SFMx) Sulphadiazine (mg SFD) Albucid (mg mL­1 SFA) Locula (mg mL­1 SFA) Label claim 400 500 10 10 Proposed method 398.00 ± 0.70 497.00 ± 0.50 9.90 ± 0.30 9.85 ± 0.20 BP method (4) 397.00 ± 0.60 496.00 ± 0.60 9.90 ± 0.30 9.80 ± 0.30 Reported method (21) 397.00 ± 0.80 496.00 ± 0.80 9.75 ± 0.30 9.78 ± 0.30 t-value F-value 2.29 2.29 2.48 2.50 1.44 1.44 2.25 1.96 a Mean ± SD, n = 6. Theoretical t-value = 2.776; theoretical F-value = 6.39. Table VI. Comparison of reported spectrophotometric methods with the proposed method Sulfonamide ëmax (nm) analyzed SFMx and SFD SFA SFG 500 525 450 Beer's law limits (mg mL­1) 10­50 10­70 Not reported 0.1­7.0 1.65 ´ 104 Molar absorptivity Reference (L mol­1 cm­1) 25 26 27 Reagent(s) used p-Benzoquinone o-Chloranil Phenol and sodium hypochlorite Dopamine Remark heating is needed SFMx 2.67 ´ 104 diazotisation coupling, product is complexaton with molybdate diazotization of drug followed by coupling with 8-HQ 8-Hydroxyquinoline (8-HQ) SFMx 0.2­6.0 3.38 ´ 104 this paper The proposed method was found to be simple, rapid, selective and more sensitive than most of the spectrophotometric methods available in literature. It does not involve heating, extraction and consumes less time. The products are stable for a sufficient interval of time making the method useful in practice. CONCLUSIONS The proposed method is simple, sensitive and free from drastic experimental conditions such as heating. It is also accurate and precise enough to be successfully adopted as an alternative to the existing spectrophotometric method and evaluation of drugs in pharmaceutical preparations to assure a high standard of quality control. Acknowledgements. ­ One of the authors (Shailendra D. Naik) thanks the University of Mysore for the support to this research work.

Journal

Acta Pharmaceutica – de Gruyter

Published: Sep 1, 2007

There are no references for this article.